New hope for rare immune disorder: ruxolitinib trial targets castleman disease
NCT ID NCT07085039
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 29 times
Summary
This study tests the drug ruxolitinib in adults with a rare immune disorder called idiopathic multicentric Castleman disease (iMCD) that did not get better with standard treatments like siltuximab or tocilizumab. The goal is to see if ruxolitinib can improve symptoms, lab results, and lymph node size. About 14 people will take part in this single-arm, open-label trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTLEMAN'S DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.